• Policy
• MSD begins cervical cancer trials for its drug candidate
• by Lee, Hye-Kyung Jul 18, 2024 05:48am

• Policy
• Ilaris, Orkedia, Latuda will likely be reimbursed next month
• by Lee, Tak-Sun Jul 17, 2024 05:50am

• Policy
• AbbVie renews RSA for leukemia drug 'Venclexta'
• by Lee, Tak-Sun Jul 17, 2024 05:50am

• Policy
• Temp reimb extension for antivirals including Tamiflu ends
• by Lee, Tak-Sun Jul 16, 2024 05:46am

• Policy
• ‘Exclude GER and CAN or cut price by 50% less'
• by Lee, Tak-Sun Jul 15, 2024 05:48am

• Policy
• Roche Korea speeds up reimb of Ocrevus in KOR
• by Lee, Tak-Sun Jul 12, 2024 05:48am

• Policy
• Reassessing the plan for comparing foreign drug prices
• by Lee, Tak-Sun Jul 12, 2024 05:48am

• Policy
• ‘Bioequivalence tests rather intensified price cuts'
• by Lee, Tak-Sun Jul 12, 2024 05:47am

• Policy
• Simulect in supply crisis with no alternative
• by Lee, Tak-Sun Jul 11, 2024 05:47am

• Policy
• Debate within the Health and Welfare Committee members
• by Lee, Jeong-Hwan Jul 10, 2024 05:48am